Gain Therapeutics (GANX) Competitors $2.27 -0.07 (-2.99%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.40 +0.13 (+5.51%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends GANX vs. GOSS, BTMD, ITOS, LFVN, ACIU, CGC, AVIR, AMLX, BNTC, and HRTXShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Gossamer Bio (GOSS), biote (BTMD), iTeos Therapeutics (ITOS), LifeVantage (LFVN), AC Immune (ACIU), Canopy Growth (CGC), Atea Pharmaceuticals (AVIR), Amylyx Pharmaceuticals (AMLX), Benitec Biopharma (BNTC), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Gossamer Bio biote iTeos Therapeutics LifeVantage AC Immune Canopy Growth Atea Pharmaceuticals Amylyx Pharmaceuticals Benitec Biopharma Heron Therapeutics Gain Therapeutics (NASDAQ:GANX) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Do insiders and institutionals hold more shares of GANX or GOSS? 12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 11.7% of Gain Therapeutics shares are held by insiders. Comparatively, 5.0% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend GANX or GOSS? Gain Therapeutics presently has a consensus target price of $7.25, indicating a potential upside of 219.38%. Gossamer Bio has a consensus target price of $9.20, indicating a potential upside of 557.14%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Gain Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor GANX or GOSS? In the previous week, Gossamer Bio had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 1 mentions for Gossamer Bio and 0 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.00 equaled Gossamer Bio'saverage media sentiment score. Company Overall Sentiment Gain Therapeutics Neutral Gossamer Bio Neutral Is GANX or GOSS more profitable? Gossamer Bio's return on equity of -127.28% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gain TherapeuticsN/A -203.91% -128.05% Gossamer Bio N/A -127.28%-22.12% Which has better earnings & valuation, GANX or GOSS? Gain Therapeutics has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGain Therapeutics$50K1,204.01-$22.27M-$1.10-2.06Gossamer BioN/AN/A-$179.82M-$0.32-4.38 Which has more volatility & risk, GANX or GOSS? Gain Therapeutics has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Does the MarketBeat Community favor GANX or GOSS? Gossamer Bio received 117 more outperform votes than Gain Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Gain Therapeutics an outperform vote while only 66.38% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformGain TherapeuticsOutperform Votes3571.43% Underperform Votes1428.57% Gossamer BioOutperform Votes15266.38% Underperform Votes7733.62% SummaryGossamer Bio beats Gain Therapeutics on 9 of the 16 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.07M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-2.065.4725.4719.00Price / Sales1,204.01306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book2.346.717.644.62Net Income-$22.27M$138.33M$3.18B$245.85M7 Day Performance-16.85%-2.61%-1.99%-2.68%1 Month Performance6.57%-2.32%-0.42%-2.19%1 Year Performance-48.87%-5.31%16.51%12.84% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics2.1425 of 5 stars$2.27-3.0%$7.25+219.4%-48.6%$62.07M$50,000.00-2.0620Gap UpGOSSGossamer Bio3.9776 of 5 stars$1.17+10.4%$9.20+686.3%+14.8%$265.12MN/A-3.66180High Trading VolumeBTMDbiote3.3529 of 5 stars$4.83+5.9%$10.00+107.0%-9.5%$262.46M$185.36M18.58194ITOSiTeos Therapeutics3.2727 of 5 stars$7.18-5.4%$22.25+209.9%-29.8%$262.29M$12.60M-2.2890Positive NewsLFVNLifeVantage4.1084 of 5 stars$20.72+7.3%$30.50+47.2%+139.1%$260.06M$212.15M37.00260ACIUAC Immune2.2079 of 5 stars$2.61-3.0%$12.00+359.8%-21.0%$258.23M$40.97M-5.67140News CoveragePositive NewsGap UpCGCCanopy Growth1.7361 of 5 stars$1.97-2.5%$2.00+1.5%-52.6%$256.95M$220.27M-0.401,029AVIRAtea Pharmaceuticals2.743 of 5 stars$3.04+2.0%$6.88+126.3%-26.6%$256.76MN/A-1.4770AMLXAmylyx Pharmaceuticals2.5446 of 5 stars$3.74-1.6%$7.33+96.1%-78.4%$256.38M$380.79M-0.98200Upcoming EarningsBNTCBenitec Biopharma2.7665 of 5 stars$10.88+3.5%$24.43+124.5%+211.4%$252.59M$80,000.000.0020Earnings ReportAnalyst ForecastNews CoverageGap UpHRTXHeron Therapeutics3.8107 of 5 stars$1.66-4.6%$5.67+241.4%-37.1%$252.49M$127.04M-9.22300 Related Companies and Tools Related Companies Gossamer Bio Alternatives biote Alternatives iTeos Therapeutics Alternatives LifeVantage Alternatives AC Immune Alternatives Canopy Growth Alternatives Atea Pharmaceuticals Alternatives Amylyx Pharmaceuticals Alternatives Benitec Biopharma Alternatives Heron Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GANX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GANX Stock Alerts